Sam Altman is currently driven by Information Technology. The recent article tape shows 32 bullish, 26 bearish, and 14 neutral reads across 5 sources.
Updated 31 Aug 2026, 6:39 pm IST · Sentiment is computed from saved analyzed news and quote snapshots.
Sam Altman has 80 recent analyzed stories in this hub, with a sector bias score of +11. The dominant cluster is Information Technology, and the story breadth is 32 bullish, 26 bearish, and 14 neutral reads.
The most repeated listed names are DALMIASUG, JBCHEPHARM, PANACEABIO, STAR, AUROPHARMA. These are the names drawing the most coverage; quote movement, volume, and company-specific context add further reference.
USFDA approvals for complex generics are crucial for Indian pharma, opening large market opportunities. Competition is expected but market size is significant.
Economic Times · 12 hr ago · 2 min read
Mint · 15 hr ago · 2 min read
Mint · 15 hr ago · 2 min read
Economic Times · 1 day ago · 2 min read
Economic Times · 1 day ago · 2 min read
Sam Altman coverage is leaning bullish across 80 recent stories from 5 sources. The article split is 32 bullish, 26 bearish, and 14 neutral.
The strongest article-driven stock reads in this hub are DALMIASUG (+76), PANACEABIO (+63), STAR (+63). These scores are based on saved article impact, not a standalone buy signal.
The weakest article-driven stock reads in this hub are JBCHEPHARM (-63), BAJAJ-AUTO (-60), BSE (-60). Check quote confirmation and fresh coverage before acting.
Recent Sam Altman coverage is clustering around Information Technology, Financial Services, Automobiles.